Free morning briefing · 07:30 weekdays
The RNS that moves prices, in your inbox before the open.
AI-ranked movers and high-impact RNS across the FTSE 100, 250, SmallCap and AIM — one short email, every market day.
Get the briefing
AVCT

Avacta Group Plc

AVCTLSEUnited KingdomHealthcareBiotechnologyFTSE AIM 100

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe…more

P/B110.47x
£310.56M
Market Cap
EV: £301.13M
MOM8
QUAL—
VAL—
RSK8
AVCT
£310.56M
Market Cap · EV £301.13M

Avacta Group Plc

MOM8
QUAL—
VAL—
RSK8

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe…more

Latest RNS from Avacta Group Plc

Analyst consensus: Hold

As of 22 Sept 2026, 2 analysts rate Avacta Group Plc a Hold, with 50% buy ratings and a mean price target of 94p (range 60p–122p), +21% vs the current price.

Strong buy: 0Buy: 1Hold: 1Sell: 0Strong sell: 0

Full analyst history →

More Healthcare companies